Funding for this research was provided by:
Center for Information Technology (R01DC017117)
Received: 13 May 2019
Accepted: 11 September 2019
First Online: 30 September 2019
: The authors declare the following competing interests. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. B.P.K. and J.K.J. are inventors on various patents and patent applications that describe gene editing and epigenetic editing technologies. S.Q.T. is a co-inventor on patents and patent applications describing gene editing technologies and methods for defining their genome-wide activities. S.Q.T. is a member of the scientific advisory board of Kromatid Inc. J.S.C and N.E.B are co-inventors on muscle-specific gene editing patents; JSC has financial interests in Solid Biosciences. C.A.M. has a financial interest in Chameleon Biosciences, Inc., a company developing an enveloped adeno-associated virus (AAV) vector platform technology for repeated dosing of systemic gene therapy. M.J.A. holds equity in Excelsior Genomics. J.K.J, C.A.M., and M.J.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.